BSL3 Enhancements for RNA Virus Pandemic Preparedness

BSL3 针对 RNA 病毒大流行防范的增强

基本信息

批准号：
10611745
负责人：
Hardy Kornfeld
金额：
$ 399.42万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-16 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10611745
关键词：
2019-nCoV Address Air Alphavirus Ambulatory Care Animals Avian Influenza A Virus Award Back Basic Science Biotechnology COVID-19 COVID-19 pandemic Carbon Dioxide Chikungunya virus Clinical Research Clinical Trials Communicable Diseases Communication Complement Coronavirus Department of Defense Drug resistance Ensure Equipment FDA approved Faculty Foundations Freezing Funding Goals Hamsters Hantavirus Housing Immune Immunoglobulin A In Vitro Incubators Infectious Diseases Research Innovative Therapy Institutes Institution Integration Host Factors International Laboratories Manuscripts Massachusetts Modernization Nature Newcastle disease virus Pathogenicity Patients Positioning Attribute Prevention Prevention strategy Privatization Procedures Productivity Protocols documentation RNA RNA Viruses RNA vaccine Research Research Institute Research Personnel Research Project Grants Resources SARS coronavirus SARS-CoV-2 pathogenesis Safety Sampling Security Services Site Structure System Therapeutic Time Translating Translational Research United States National Institutes of Health Universities Update Virus Diseases Virus-like particle Work Zika Virus base bench to bedside biosafety level 3 facility cost design experience hemorrhagic fever virus humanized mouse in vivo innovation instrument medical schools member mouse model novel operation pandemic disease pandemic preparedness pathogen pathogenic bacteria pathogenic virus programs recruit repaired research study resilience square foot therapeutic RNA translational potential translational study treatment strategy vaccine development vaccine strategy ventilation

项目摘要

Program Summary/Abstract The University of Massachusetts Chan Medical School (UMass Chan) seeks NIH G20 funding to repair, renovate, and modernize the existing Biosafety Level 3 (BSL3) and Animal BSL3 (ABSL3) facilities to enhance current research on RNA viruses of pandemic potential. As an internationally recognized leader in infectious disease research, UMass Chan has made pivotal contributions to this field, including work on the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), highly pathogenic avian influenza virus, Newcastle disease virus, and Zika virus. At the start of the coronavirus 2019 (COVID-19) pandemic, we quickly became one of the leading institutes for research and clinical trials on SARS-CoV-2. Our researchers obtained several awards from the NIH, NSF, and Department of Defense, as well as private foundations for these studies. As a leading site for COVID-19 clinical trials, UMass Chan is uniquely poised to bridge clinical and basic research studies on these RNA viruses by enabling essential research on patient samples to complement in vitro and in vivo studies. Our findings can be translated to develop novel prevention and therapeutic strategies leveraging our world-renowned RNA Therapeutics Institute, our Institute for Drug Resistance, and our partnership with MassBiologics for vaccine development, making UMass Chan a powerhouse for bench-to-bedside translational research. The UMass Chan BSL3 Core Laboratories have seen a staggering increase in usage due to the pandemic. Our BSL3 and ABSL3 facilities need major updates and renovations to keep pace with our research programs and continue to provide a safe, modern, and efficient lab for BSL3 work. The last time these facilities were completely renovated was over a decade ago (2003–2005 for our ABLS3 and 2010–2014 for our BSL3). We will modernize the existing BSL3 and ABSL3 facilities by updating the ceiling and ventilation systems, installing new autoclaves, maximizing the existing footprint by removing outdated equipment, and updating cameras for safety. These updates will significantly enhance research on RNA viruses of pandemic potential by addressing deficiencies that have caused prolonged downtime for repairs, and by enhancing the resilience of critical building systems. Our UMass Chan Facilities and Campus Services team has extensive experience executing design, renovations, and oversight of the operations and have worked with the NIH on previous G20 and C06- funded improvements to our facilities. The G20 funding will also be backed by strong institutional support for this project and a commitment to fully equip the updated space with state-of-the-art scientific instruments and other equipment needed to maintain the productivity of currently funded and future research on SARS-CoV-2 and other BSL3-level RNA viral pathogens. With G20 funding, our BSL3 and ABSL3 labs can get much- needed updates to support our faculty as they continue to make ground-breaking fundamental discoveries with translational potential to address SARS-CoV-2 and other RNA viruses of pandemic potential.

计划摘要/摘要马萨诸塞大学陈医学院 (UMass Chan) 寻求 NIH G20 资金来修复、翻新和现代化现有的生物安全 3 级 (BSL3) 和动物 BSL3 (ABSL3) 设施，以增强目前对具有大流行潜力的 RNA 病毒的研究是国际公认的传染病领域的领导者。疾病研究，麻省大学陈教授在这一领域做出了关键贡献，包括在严重急性疾病方面的工作呼吸综合征冠状病毒-2 (SARS-CoV-2)、高致病性禽流感病毒、新城疫病毒和寨卡病毒在 2019 年冠状病毒 (COVID-19) 大流行开始时，我们很快成为其中之一。我们的研究人员获得了 SARS-CoV-2 领先研究和临床试验机构的多项奖项。 NIH、NSF 和国防部以及这些研究的私人基金会。 COVID-19 临床试验，麻省大学陈博士独特地准备将这些研究的临床和基础研究联系起来 RNA 病毒通过对患者样本进行必要的研究来补充我们的体外和体内研究。研究结果可以转化为利用我们世界知名的技术开发新的预防和治疗策略 RNA 治疗研究所、我们的耐药性研究所以及我们与 MassBiologics 的疫苗合作伙伴关系发展，使麻省大学陈成为实验室到临床转化研究的强大动力。由于大流行，麻州大学陈 BSL3 核心实验室的使用量出现了惊人的增长。我们的 BSL3 和 ABSL3 设施需要进行重大更新和翻新，以跟上我们的研究计划的步伐并继续为 BSL3 工作提供安全、现代化、高效的实验室。完全翻新是在十多年前（ABLS3 为 2003 年至 2005 年，BSL3 为 2010 年至 2014 年）。将通过更新天花板和通风系统、安装新的高压灭菌器，通过拆除过时的设备来最大化现有的占地面积，并更新相机这些更新将通过解决大流行潜力的 RNA 病毒的研究得到显着加强。导致维修停机时间延长的缺陷，并通过增强关键的恢复能力我们的麻省大学陈设施和校园服务团队拥有丰富的执行经验。设计、翻新和运营监督，并在之前的 G20 和 C06 项目中与 NIH 合作 G20 的资金也将得到强有力的机构支持的支持。该项目以及为更新后的空间配备最先进的科学仪器的承诺维持当前资助的和未来的 SARS-CoV-2 研究生产力所需的其他设备和其他 BSL3 级别的 RNA 病毒病原体有了 G20 的资助，我们的 BSL3 和 ABSL3 实验室可以获得很多- 需要更新来支持我们的教师，因为他们继续做出突破性的基本发现解决 SARS-CoV-2 和其他具有大流行潜力的 RNA 病毒的转化潜力。